News round-up by DDW’s Megan Thomas for 15-19 November
As the world emerges from the Covid-19 pandemic, DDW’s Megan Thomas has rounded up five stories which show how the drug discovery industry has used what it has learnt over the last two years to innovate for the future, as well as how it continues to look for ways to make the virus more manageable and less deadly.
Beximco Pharmaceuticals has launched a generic molnupiravir, an oral antiviral drug for symptomatic Covid-19 patients developed by Merck, Sharp & Dohme (MSD) and Ridgeback Biotherapeutics, following Emergency Use Authorisation by the Directorate General of Drug Administration (DGDA), the regulatory authority in Bangladesh.
Birmingham Biotech and the University of Birmingham have signed a licensing agreement to commercialise a novel anti-viral nasal spray that protects against Covid-19. The formulation was engineered by Professor Liam Grover, from the university’s Healthcare Technologies Institute, and a team of researchers who also collaborated on its testing.
CN Bio has entered a research collaboration with the Infection Innovation Consortium (iiCON) to validate the next generation of Covid-19 research tools.
Evonik met with a delegation of representatives from Canada at its site in Darmstadt to discuss competencies in lipid nanoparticles at Evonik’s Vancouver laboratories and evaluate future collaboration opportunities.
Emergex Vaccines has announced that it has received the necessary regulatory approvals to initiate a Phase I clinical trial to evaluate the safety and tolerability of its vaccine candidate for SARS-CoV-2.